CEO Dawn Bitz

Yesterday it was announced that Adherium has appointed a new CEO. Dawn Bitz.

To be honest, I’ve become pretty dubious about the leadership changes we’ve seen over the years. We haven’t had much luck—and let’s be real, our last CEO... that was a bit of a fiasco.

That said, I’m choosing to look forward, and I decided to do a bit of homework on Dawn Bitz, our new CEO. I wanted to see if she brings some fresh energy and real potential for Adherium—and I’ve got to say, I’m actually encouraged.

From what I’ve found, Dawn seems to be the strongest CEO we’ve had yet, with a far better track record than any of her predecessors. She has nearly three decades of global medtech experience, with serious credentials in respiratory care, commercial scaling, and regulatory strategy. She’s managed P&Ls up to US$500 million, launched successful product lines, secured major funding, and worked with industry leaders like Medtronic and Boston Scientific.

She also seems younger than past CEO's and driven enough to throw everything at this and help turn things around.

Here’s what I’ve dug up so far about her background and what she could bring to the table for ADR:


Game-Changing Leadership for ADR
Adherium (ASX:ADR) has just made what could be its most strategic move to date—appointing seasoned medtech executive Dawn Bitz as CEO, effective 22 July 2025.
This is not just another CEO shuffle—this is a commercial upgrade.

Why Dawn Bitz Could Be a Turning Point
With over 27 years of experience in global medical device commercialization, Dawn brings serious credentials:

• Managed global P&Ls up to US$500 million
• Launched medtech products with revenues from US$25M to $150M
• Led commercialization in respiratory, critical care, and digital health
• Secured funding via grants, equity, and M&A worth hundreds of millions
• Expert in FDA regulatory pathways—PMA, 510(k), De Novo

This is exactly the kind of operator you want when you’re not just trying to invent, but scale.

Why She’s Different From Past CEOs
Past ADR leaders brought great insight in R&D, tech, or digital health—but Dawn is a go-to-market executor.
She’s a builder of commercial teams, a driver of strategic partnerships, and knows how to turn smart devices into global revenue. She’s worked with giants like Medtronic, Boston Scientific, and UCB Pharma, giving her unmatched insight into hospital systems, payer networks, and healthcare procurement.

The Right Person for the Right Phase
Adherium has spent years developing proven technology like the Hailie® sensor platform. Now it needs someone who knows how to:

• Expand market share
• Navigate complex health systems
• Secure reimbursement channels
• Forge commercial deals that scale revenue globally

That’s Dawn’s sweet spot.

✨ Final Take
This is the kind of leadership you appoint when you're serious about becoming a dominant player in respiratory digital health. For long-time holders who’ve endured ups and downs, this appointment could be the inflection point.
With the right support from the board and shareholders, Dawn Bitz might be the CEO that finally unlocks ADR’s full potential.

Let’s go.






Let’s hope this marks a genuine shift in direction and that we finally have the leadership to match the tech we’ve built.

#Adherium #ADR #NewCEO #DawnBitz #TurningPoint #LongADR